By Fineline Cube China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced a significant licensing agreement with US-based biotech firm One Bio Inc. The agreement pertains to Hengrui’s Category 1 product, SHR1905, a hymic stromal lymphopoietin (TSLP)-targeted monoclonal antibody (mAb). Under the terms of the deal, One Bio will obtain exclusive development, manufacturing, and commercialization rights for the drug outside the Greater China territory.
Financial Terms and Commitments
As part of the agreement, One Bio will pay Hengrui an upfront fee of USD 25 million and is committed to making up to USD 1.025 billion in milestone payments. Additionally, One Bio will provide Hengrui with a double-digit royalty based on the annual sales of SHR1905, highlighting the potential commercial value of the drug.
Potential Applications and Regulatory Approvals for SHR-1905
SHR-1905 is anticipated to be a suitable treatment for broad severe asthma and was approved for study in this indication in China in May 2021. Furthermore, in May of this year, SHR-1905 received a trial nod in China for the treatment of chronic sinusitis with nasal polyps, expanding its potential therapeutic applications.-Fineline Info & Tech